BRPI0516027A - compostos de sulfonamida - Google Patents

compostos de sulfonamida

Info

Publication number
BRPI0516027A
BRPI0516027A BRPI0516027-8A BRPI0516027A BRPI0516027A BR PI0516027 A BRPI0516027 A BR PI0516027A BR PI0516027 A BRPI0516027 A BR PI0516027A BR PI0516027 A BRPI0516027 A BR PI0516027A
Authority
BR
Brazil
Prior art keywords
sulfonamide compounds
cck1
cck2
compounds
treatment
Prior art date
Application number
BRPI0516027-8A
Other languages
English (en)
Inventor
Brett Allison
Victor K Phuong
Marna C W Pippel
Michael H Rabinowitz
Hariharan Venkatesan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0516027A publication Critical patent/BRPI0516027A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

COMPOSTOS DE SULFONAMIDA. A presente invenção refere-se a certos compostos de sulfonamida são inibidores duais de CCK1/CCK2 úteis no tratamento de doenças mediadas por CCK1/CCK2.
BRPI0516027-8A 2004-09-24 2005-09-19 compostos de sulfonamida BRPI0516027A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61272004P 2004-09-24 2004-09-24
PCT/US2005/033692 WO2006036670A1 (en) 2004-09-24 2005-09-19 Sulfonamide compounds

Publications (1)

Publication Number Publication Date
BRPI0516027A true BRPI0516027A (pt) 2008-08-19

Family

ID=35781432

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516027-8A BRPI0516027A (pt) 2004-09-24 2005-09-19 compostos de sulfonamida

Country Status (18)

Country Link
US (3) US7297816B2 (pt)
EP (1) EP1797083A1 (pt)
JP (1) JP2008514608A (pt)
KR (1) KR20070057252A (pt)
CN (1) CN101061116A (pt)
AR (1) AR050953A1 (pt)
AU (1) AU2005289887A1 (pt)
BR (1) BRPI0516027A (pt)
CA (1) CA2581426A1 (pt)
CR (1) CR9080A (pt)
EA (1) EA200700717A1 (pt)
EC (1) ECSP077360A (pt)
IL (1) IL182149A0 (pt)
MX (1) MX2007003623A (pt)
NO (1) NO20072092L (pt)
PE (1) PE20060823A1 (pt)
WO (1) WO2006036670A1 (pt)
ZA (1) ZA200702452B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1651621T3 (da) * 2003-08-08 2008-11-10 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
CN101061116A (zh) 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102648183B (zh) 2009-10-07 2015-12-02 卡罗生物股份公司 作为***受体配体的取代吡唑
MX337575B (es) 2009-10-09 2016-03-10 Zafgen Corp Compuestos de sulfona y métodos para lafabricación y uso de éstos.
KR20130043207A (ko) 2010-07-22 2013-04-29 자프겐 인크. 트리시클릭 화합물 및 이의 제조 및 사용 방법
MX344238B (es) 2011-01-26 2016-12-07 Zafgen Inc Compuestos de tetrazol y métodos para preparar y usar los mismos.
WO2012154678A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic sulfonamide compounds and methods of making and using same
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
TW201321371A (zh) 2011-10-14 2013-06-01 Incyte Corp 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
AU2013209723B2 (en) 2012-01-18 2016-11-24 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
WO2013186089A2 (en) 2012-06-14 2013-12-19 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests
AU2013337282A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds and methods of making and using same
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
MX2015005733A (es) 2012-11-05 2016-02-10 Zafgen Inc Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
CN103183623A (zh) * 2013-03-12 2013-07-03 中国医学科学院医药生物技术研究所 一组苯磺酰胺基苯甲酰胺类衍生物及制备和应用
PL3071206T3 (pl) 2013-11-22 2022-01-17 CL BioSciences LLC Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie
EP3087069B1 (en) * 2013-12-23 2019-01-30 Norgine B.V. Compounds useful as ccr9 modulators
SG10201710436WA (en) 2014-02-03 2018-01-30 Quadriga Biosciences Inc Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
US9394236B2 (en) 2014-02-03 2016-07-19 Quadriga Biosciences, Inc. β-substituted γ-amino acids and analogs as chemotherapeutic agents
TWI665178B (zh) 2015-08-03 2019-07-11 夸德里加生物科學公司 作為化療劑的β－取代的β－氨基酸和類似物及其應用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT77219B (fr) 1982-08-24 1986-02-04 May & Baker Ltd Procede de preparation des derives de la benzamide
KR0143565B1 (ko) * 1988-06-13 1998-07-15 사노 가즈오 피발산의 p-치환된 페닐 에스테르 유도체, 그의 제조 방법 및 이를 포함하는 조성물.
CA2057324A1 (en) * 1990-12-18 1992-06-19 Lora Louise Fitch Benzamide and sulfonamide hypoglycemic agents
IL101514A (en) 1991-04-10 1996-01-31 Merck & Co Inc History of benzodiazepines and anticoagulants containing cholecystokinin containing them
FR2703995B1 (fr) * 1993-04-16 1995-07-21 Sanofi Elf 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
AU721081B2 (en) 1996-12-10 2000-06-22 Zeria Pharmaceutical Co., Ltd. 1,5-benzodiazepine derivatives
JP2003502347A (ja) 1999-06-24 2003-01-21 スミスクライン・ビーチャム・コーポレイション マクロファ−ジスカベンジャ−受容体アンタゴニスト
WO2001053331A2 (en) * 2000-01-24 2001-07-26 Adherex Technologies, Inc. Peptidomimetic modulators of cell adhesion
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) * 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
ITTO20020674A1 (it) 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
RS20050733A (en) 2003-03-28 2007-06-04 Janssen Pharmaceutica N.V., Benzo/1,2,5/thiadiazole compounds
GB0312360D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 4-amino-2(5H)-furanones
GB0312368D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
US20050042283A1 (en) 2003-07-11 2005-02-24 University Of Massachusetts Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
DK1651621T3 (da) 2003-08-08 2008-11-10 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
CN101061116A (zh) 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物

Also Published As

Publication number Publication date
US20100292240A1 (en) 2010-11-18
CR9080A (es) 2008-09-09
MX2007003623A (es) 2007-09-11
US7855292B2 (en) 2010-12-21
JP2008514608A (ja) 2008-05-08
PE20060823A1 (es) 2006-09-23
AR050953A1 (es) 2006-12-06
KR20070057252A (ko) 2007-06-04
US20080132511A1 (en) 2008-06-05
US20060069286A1 (en) 2006-03-30
CA2581426A1 (en) 2006-04-06
EA200700717A1 (ru) 2007-10-26
IL182149A0 (en) 2007-07-24
WO2006036670A1 (en) 2006-04-06
US7297816B2 (en) 2007-11-20
CN101061116A (zh) 2007-10-24
ECSP077360A (es) 2007-04-26
EP1797083A1 (en) 2007-06-20
NO20072092L (no) 2007-06-22
AU2005289887A1 (en) 2006-04-06
ZA200702452B (en) 2009-05-27

Similar Documents

Publication Publication Date Title
BRPI0516027A (pt) compostos de sulfonamida
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
EA201070247A1 (ru) Ингибиторы протеасом
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA200702567A1 (ru) Ингибиторы дипептидил пептидазы iv, основанные на пирролопиридине
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
EA200802054A1 (ru) Ингибиторы фермента
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
TW200509892A (en) Novel aminobenzophenone compounds
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
NO20085029L (no) Substituerte pyridylamidforbindelser som modulatorer av histamin H3 reseptoren
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
EA200900261A1 (ru) Применение эсцина
ATE472324T1 (de) Isosorbid-mononitrat-derivate zur behandlung von okularer hypertonie
EA200701852A1 (ru) Производные аминокислот
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
CL2009001436A1 (es) Compuestos cristalinos de (1r,2s,3r)-1-(2-isoxazol-3-il)-1himidazol-4-il)butano-1,2,3,4-tetraol; utiles en el tratamiento y/o prevencion de asma, esclerosis multiple, artritis reumatoide, entre otras enfermedades.
EA201001517A1 (ru) Замещенные пиперидины в качестве терапевтических соединений

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.